The intent of pharmacogenetics
Dose of drugs - no longer a problem?
In daily routine, a drug can show different efficacy and tolerability in individual subjects. The different reactions are frequently based on genetic variants (e.g. SNP on the protein-coding range) of proteins that take part in drug-metabolism:
- metabolic enzymes (e.g. Cytochrom P450 enzyme system)
- transport proteins (e.g. MDR I & II)
- receptors (e.g. PPARg)
By application of pharmacogenetic diagnostics the dose of a drug can be selected, adapted to the genotype of the patient and toxicity may therefore be reduced.
The selection and dosage of drugs is no longer a problem
By utilizing specific test procedures, pharmacogentics enables us to determine how, and in which way, one individual may react to certain drugs. We offer you the possibility to determine the individual effectiveness of your drug in advance.
Your advantages:
- pharmacogenetic test procedures significantly increase the efficiency and safety for the individual dosage of drugs in a very significant manner
- the recruitment of patients and volunteers for specific studies can be targeted directly and much more efficiently
- the correct treatment selection can be achieved faster, easier and safer for both, physicians and patients.
Do you have drugs with high variability in activity under development?
Do you plan clinical trials with those drugs?
Do you have already examined those drugs in clinical trials and experienced problems in association with dose finding?
If you have answered one of these questions with yes, contact us. We may be able to help you to solve these issues.
The list below shows the actual available genotyping possibilities.
New parameters that fit your specific needs can be implemented by our group on a short time basis.
Parameter
| 1 | APOE*C112T /*C158T | 11 | CYP4B1*2 /*3 /*4 /*5 | |
|---|---|---|---|---|
| 2 | COMT* V158M | 12 | GSTM1 Deletion | |
| 3 | CYP1A1*2A | 13 | GSTP1*I105V | |
| 4 | CYP1A2*1C /*1F | 14 | GSTT1 Deletion | |
| 5 | CYP2C19*2 /*3 | 15 | MDR1*C3435T | |
| 6 | CYP2C8*2 /*3 /*4 | 16 | NAT1*3 /*10 /*11 /*14 /*17 | |
| 7 | CYP2C9*2 /*3 | 17 | NAT2*5A /*6A /*7A/B /*14A | |
| 8 | CYP2D6*3 /*4 /*5 /*6 | 18 | PC-1* K121Q | |
| 9 | CYP3A4*1B /*2 /*3 /*17 | 19 | PPARG*P12A | |
| 10 | CYP3A5*2 /*3 | 20 | TPMT*G238C /*G460A /*A719G | |
| | | 21 | Laktase Intoleranz (-13910 T/C) |
Award
For our research work in the area of pharmacogenetics ikfe received in December 2006 an innovation award from the Federal State of Rheinland-Pfalz.
